The PIDTC will have several levels of responsibility for decision-making and administration (Figure 1). The Administrative Unit under the direction of Morton J. Cowan, PI, is responsible for the overall administration of the PIDTC. Dr. Cowan's background and experience is provided in detail in Section V. Overall Clinical Research Program, Leadership and Resources of the proposal. The Administrative Unit will manage center contracts, monitor individual center activities through enrollment and participation on the Scientific Planning Committee, communication with center data managers, support of centers with respect to obtaining IRB approval and submission of data to the USIDNET, CIBMTR and DMCC, and arrangement of conference calls and travel to RDCRC meetings. As PI, Dr. Cowan will be responsible for the overall management of the consortium. He will direct the Administrative Unit of the PIDTC and lead the Steering Committee and the Scientific Planning Committee. He will adjudicate conflicts within the consortium and will ensure that the Advisory Committee and ORD/NIAID administrators are kept up to date with the progress of the PIDTC and he will work with NIAID and ORD administrators and other consortia directors to ensure that the goals of the consortia are met. He will also represent the PIDTC in the ASBMT, BMTCTN and PBMTC and with other groups outside the US and Canada, in particular, the Immunodeficiency Committee of the EBMT and the ESID and along with Project Pis and the co-Pi represent the PIDTC with the RDCRC administrators and other Pis.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-HOP-Y)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Burbank, Allison J; Shah, Shaili N; Montgomery, Maureen et al. (2016) Clinically focused exome sequencing identifies an homozygous mutation that confers DOCK8 deficiency. Pediatr Allergy Immunol 27:96-8
Cowan, Morton J (2016) The Primary Immune Deficiency Treatment Consortium: how can it improve definitive therapy for PID? Expert Rev Clin Immunol 12:1007-9
Griffith, Linda M; Cowan, Morton J; Notarangelo, Luigi D et al. (2016) Primary Immune Deficiency Treatment Consortium (PIDTC) update. J Allergy Clin Immunol 138:375-85
Chan, Alice Y; Punwani, Divya; Kadlecek, Theresa A et al. (2016) A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70. J Exp Med 213:155-65
De Ravin, Suk See; Wu, Xiaolin; Moir, Susan et al. (2016) Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 8:335ra57
Jackson, Shaun W; Scharping, Nicole E; Jacobs, Holly M et al. (2016) Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell Activation. J Immunol 197:4529-4534
Punwani, Divya; Kawahara, Misako; Yu, Jason et al. (2016) Lentivirus Mediated Correction of Artemis-deficient Severe Combined Immunodeficiency. Hum Gene Ther :
Punwani, Divya; Zhang, Yong; Yu, Jason et al. (2016) Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B. N Engl J Med 375:2165-2176
Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66
Chinen, Javier; Notarangelo, Luigi D; Shearer, William T (2016) Advances in clinical immunology in 2015. J Allergy Clin Immunol 138:1531-1540

Showing the most recent 10 out of 64 publications